Effects of 8-epi-PGF2alpha on isolated bronchial smooth muscle of healthy and heaves-affected horses.

The research article focuses on studying the effects of the prostaglandin-like compound, 8-epi-PGF2alpha, as a potential bronchoconstrictor on healthy and heaves-affected horses. The findings suggest that while 8-epi-PGF2alpha holds minor importance as a bronchoconstrictor in healthy horses, its efficacy denotes a significant increase in those horses affected by heaves.

Focus of the Research

• The research explores the effects of 8-epi-PGF2alpha, a compound produced during oxidative stress, on bronchial smooth muscle (BR) in both healthy and heaves-affected horses. The term “heaves” refers to a chronic obstructive pulmonary disease found in horses.
• 8-epi-PGF2alpha has already been confirmed as an in vitro bronchoconstrictor in healthy laboratory animals and humans. However, its role in diseased airways is a novel concept and forms the basis of this study.

Methodology and Results

• The study compares the maximal effect and potency of 8-epi-PGF2alpha with other bronchoconstrictive agents such as Acetylcholine (ACh), steroids (PGF2alpha), and synthetic receptor agonist (U46619).
• Researchers also evaluate whether 8-epi-PGF2alpha has the potential to enhance the cholinergic responsiveness, i.e., the sensitivity to the neurotransmitter acetylcholine, of bronchial smooth muscle.
• The results revealed a rank order of efficacy, with Acetylcholine found to be the most effective bronchoconstrictor, followed by U44619, PGF2alpha, and 8-epi-PGF2alpha respectively in both healthy and heaves-affected horses.
• However, in the case of heaves-affected horses, the constrictive response triggered by 8-epi-PGF2alpha was significantly higher compared to its effect on healthy horses, while the pD2 values (a parameter that indicates the potency of a drug) remained similar.
• A subthreshold dose of 8-epi-PGF2alpha do not induce cholinergic hyper-responsiveness in either healthy or heaves-affected horses.

Conclusion

• The study concludes that 8-epi-PGF2alpha is a bronchoconstrictor of minor efficacy in healthy horses, but its effectiveness as a bronchoconstrictor increases significantly in horses affected by heaves.
• This investigation provides new insights into the effects of 8-epi-PGF2alpha in the context of pulmonary diseases, potentially paving the way for further studies investigating possible therapeutic applications of this compound on horses suffering from chronic bronchial diseases.